{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:16:14Z","timestamp":1789193774577,"version":"build-2803163510"},"reference-count":12,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,8,24]],"date-time":"2015-08-24T00:00:00Z","timestamp":1440374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008087","name":"Guthy Jackson Charitable Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008087","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical &amp; Exp Neuroim"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Neuromyelitis optica (<jats:styled-content style=\"fixed-case\">NMO<\/jats:styled-content>) is a relapsing autoimmune disease targeting the spinal cord and optic nerve leading to paralysis and blindness. Current treatment for acute <jats:styled-content style=\"fixed-case\">NMO<\/jats:styled-content> attacks is immunosuppression with high\u2010dose corticosteroids and\/or plasmapheresis. Preclinical animal studies suggest that bevacizumab might be beneficial in limiting the extent of inflammation during a <jats:styled-content style=\"fixed-case\">NMO<\/jats:styled-content> relapse by reducing the disruption of the blood\u2013brain barrier.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We carried out an open\u2010label phase 1b safety and proof\u2010of\u2010concept trial in 10 participants with <jats:styled-content style=\"fixed-case\">NMO<\/jats:styled-content> immunoglobulin G seropositive <jats:styled-content style=\"fixed-case\">NMO<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> NMO<\/jats:styled-content> spectrum disease and those at high risk for developing <jats:styled-content style=\"fixed-case\">NMO<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">NMO<\/jats:styled-content> spectrum disease who presented with an acute attack of transverse myelitis, optic neuritis or brainstem inflammation. In addition to treating with 1\u00a0g of daily intravenous methylprednisolone, we infused 10\u00a0mg\/kg of bevacizumab intravenously on day 1 of treatment. The primary outcome measure was safety and the secondary outcome measure was efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 10 participants enrolled, five presented with acute transverse myelitis, four with acute optic neuritis and one with a brainstem lesion. Bevacizumab was safe in all 10 participants, with only one serious adverse event within the 90\u2010day follow up that was not attributed to the medication. Three patients recovered to pre\u2010attack neurological function or better, and no patients required escalation to plasmapheresis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Bevacizumab is a safe add\u2010on therapy to high\u2010dose corticosteroids for NMO\/NMO spectrum disease patients presenting with an acute relapse.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cen3.12239","type":"journal-article","created":{"date-parts":[[2015,8,24]],"date-time":"2015-08-24T09:42:12Z","timestamp":1440409332000},"page":"413-418","source":"Crossref","is-referenced-by-count":41,"title":["Bevacizumab is safe in acute relapses of neuromyelitis optica"],"prefix":"10.1111","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8967-6338","authenticated-orcid":false,"given":"Maureen A.","family":"Mealy","sequence":"first","affiliation":[{"name":"Department of Neurology Johns Hopkins University Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyong","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Neurology Johns Hopkins University Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"John","sequence":"additional","affiliation":[{"name":"Department of Neurology Mount Sinai Hospital New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Levy","sequence":"additional","affiliation":[{"name":"Department of Neurology Johns Hopkins University Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,8,24]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.5692\/clinicalneurol.49.894"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.64.6.899"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2012.06.002"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.5.1107"},{"key":"e_1_2_7_6_1","volume-title":"MICROMEDEX\u00ae solutions [internet database]","year":"2015"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318204a3af"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI60842"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2011-300434"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.3109\/09638288.2013.833301"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000216139.44259.74"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70216-8"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0302-9"}],"container-title":["Clinical and Experimental Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcen3.12239","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cen3.12239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T04:20:47Z","timestamp":1696306847000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cen3.12239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,24]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1111\/cen3.12239"],"URL":"https:\/\/doi.org\/10.1111\/cen3.12239","archive":["Portico"],"relation":{},"ISSN":["1759-1961","1759-1961"],"issn-type":[{"value":"1759-1961","type":"print"},{"value":"1759-1961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,24]]}}}